Introduction
Previous studies have suggested cardioprotection from ischemia-reperfusion (I-R) injury by transforming growth factor b 1 (TGFb 1 ) despite its perceived pro-fibrotic effects. [1] [2] [3] [4] [5] [6] Binding of this growth factor to cell membrane results in the activation of the tyrosine kinase domain of receptors, 7 and consequent activation of specific signal transduction cascades, which can reach the nucleus where proliferation and differentiation are modulated. Activation of specific signal transduction cascades can directly affect the function of cellular proteins.
In in vitro studies in rat cardiac myocytes exposed to hypoxia-reoxygenation (H-R), rTGFb 1 has been shown to diminish cell injury and modulate apoptosis-related proteins 3 and iNOS expression via modulation of PKB/ Akt pathway. 4 In cultured rat cardiac myocytes, TGFb 1 seems to modify H-R-mediated injury by PKCa expression. 5 Pang et al. 8 have reported that TGFb 1 overexpression can attenuate I-R injury as well as inflammatory reaction in the brain. Others have demonstrated that the active form of TGFb 1 (TGFb 1 ACT ) in the myocardium is reduced during I-R. 9 Interestingly, cultured rat myocytes exposed to H-R exhibit a decrease in TGFb 1 ACT but an upregulation of total TGFb 1 (TGFb 1 Latent +TGFb 1 ACT ) expression. 5 This suggests that the conversion of TGFb 1 Latent to TGFb 1 ACT is defective during H-R. The increase in TGFb 1 Latent during H-R is most likely a feedback upregulation in response to the decrease in TGFb 1 ACT . TGFb 1 is synthesized in cells as a precursor molecule, TGFb 1 Latent . Conversion from cysteine (Cys 223/225 ) into serine (S 223/225 ) in the TGFb 1 Latent molecule is associated with the formation of TGFb 1 ACT . 7 It is the TGFb 1 ACT that is functionally relevant. Since TGFb 1 ACT is eliminated from blood in a few minutes, 7 providing and sustaining an effective level of TGFb 1 ACT in target tissue is difficult to obtain through systemic administration. Therefore, genetic manipulation of the tissues with TGFb 1 cDNA mutated at S 223/225 (TGFb 1 ACT ) may be an appropriate way to obtain high level of TGFb 1 ACT in tissues for prolonged period.
Development of gene therapy approach has allowed us the unique opportunity to overexpress TGFb 1 ACT and to further examine the mechanisms of modulation of I-R injury by TGFb 1 . The present study was conducted in cultured HL-1 mouse cardiomyocytes transfected with adeno-associated virus type 2 (AAV)/Neo, AAV/TGFb 1 ACT or AAV/TGFb 1 Latent , and in anesthetized rats with selective upregulation of AAV/TGFb 1 ACT in the heart.
Results
In vitro study AAV/green fluorescent protein expression. In pilot experiments, AAV/green fluorescent protein (GFP) vectors were added to cell culture dishes at multiplicity of infection (MOI) of 0-10 5 and incubated with the cells for 72 h at 37 1C in 5% CO 2 /95% air. Over 90% of the cells showed GFP expression (Figure 1a ). Since most optimal transfection was observed at an MOI of 10 Latent -transfected cells, indicating successful delivery of the transgene. In keeping with a previous study, 5 H-R itself induced the expression of TGFb 1 . It is note worthy that AAV/TGFb 1 -overexpressing cells had a greater expression of TGFb 1 . Note that AAV/Neo alone had no effect on TGFb 1 expression.
Effect of AAV/TGFb 1 transfection on cell injury and apoptosis induced by H-R. The 3-(4, 5-dimethylthiazol-2-yl)-diphenyl tetrazolium bromide (MTT) assay showed E40% decrease in viability of cells exposed to 24 h of hypoxia and 3 h of reoxygenation (H-R) (vs cells kept under control conditions) (Po0.01, Figure 1c) . The data on decrease in cell viability were consistent with the increase in lactate dehydrogenase (LDH) release ( Figure  1d ). While both TGFb 1 Latent and TGFb 1 ACT reduced the effect of H-R on cell growth and LDH release, TGFb 1 ACT was superior to TGFb 1 Latent in this regard. In keeping with the cell viability data, H-R greatly increased cardiomyocyte apoptosis as indicated by the increase in terminal deoxynucleotidyltransferasemediated dUTP-biotin nick end-labeling (TUNEL) positivity, caspase-3 activity, cytochrome c release and the expression of Bax and Bcl-2 ( Figure 2 ). AAV/TGFb 1 transfection before H-R reduced markers of apoptosis. Importantly, AAV/Neo transfection had no effect on apoptosis and the expression of apoptosis-related proteins. Further, AAV/TGFb 1 ACT was superior to AAV/ TGFb 1 Latent in terms of antiapoptotic effects (Po0.01).
AAV/TGFb 1 transfection and redox-sensitive signaling during H-R. AAV/TGFb 1 ACT or AAV/TGFb 1 Latent transfection was found to significantly reduce 2 0 , 7 0 -dihydrofluorescein (DCF) fluorescence, reflecting intracellular reactive oxygen species (ROS) level, following H-R (Po0.01, Figure 3a ). In keeping with the data on DCF Figure 3b ). We also measured the expression of redox-sensitive transcription factor NF-kB and its regulatory protein IkB-a. AAV/TGFb 1 transfection before H-R reduced the expression of NF-kB, and increased the expression of IkB-a (Po0.01, Figure 3c) ; AAV/Neo transfection had no effect on these changes. Again, TGFb 1 ACT was superior to TGFb 1 Latent in this regard.
In vivo study AAV vector inoculation. On the basis of the results of in vitro study, we chose TGFb 1 ACT rather than TGFb 1 Latent to enhance TGFb 1 expression in the rat hearts. The AAV/ GFP-treated rats displayed no adverse effects during the 6-week period of observation. After 2 or 6 weeks of intramyocardial injection of viral vectors, animals were killed by excess of CO 2 to harvest hearts. As shown in Figure 4a , TGFb 1 ACT mRNA was not seen in the AAV/ GFP-injected rat hearts, but its expression was markedly increased in the hearts injected with AAV/TGFb 1 ACT at 2 weeks and increased further at 6 weeks post-injection. PCR analysis alone gave no signal, indicating that our mRNA preparations were free of contaminating DNA. We also determined TGFb 1 ACT protein expression in the entire heart, and found it to be markedly elevated ( Figure  4b ). Further, we measured TGFb1ACT mRNA by realtime reverse transcriptase-PCR, and found it to be also dramatically increased (Figure 4c) . Importantly, the TGFb 1 ACT mRNA and protein were not upregulated in rat hearts injected with AAV alone.
As shown in Figure 4d , GFP moved away from the injection site and into the entire thickness of the heart. To examine if the gene can be expressed in the entire heart following injection at four different sites, we examined TGFb 1 ACT gene expression in multiple regions of the myocardium away from the needle site. Figure 5a shows 
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TGFb 1 upregulation in sections of myocardium 2-3 mm away from the needle site. These hearts were taken from animals transfected with AAV/TGFb 1 ACT 6 weeks earlier and subjected to I-R. Low-power view ( Â 40) showed diffuse upregulation of TGFb 1 in a 3 Â 3 mm region of the heart (determined by immunofluorescence TGFb 1 staining), whereas the high-power view ( Â 100) of selected regions demonstrated that most individual cells were TGFb 1 ACT transgene-positive. Note that there were four injections made in the left ventricular (LV) free wall and none of the regions of the LV was more than 3 mm far from the injection site. Thus most, if not all, regions of the LV showed TGFb 1 ACT gene transduction. To confirm that the increase in TGFb 1 is localized only in the hearts and not in the rest of the body, we measured plasma TGFb 1 ACT levels by enzyme-linked immunosorbent assay and TGFb 1 ACT expression in aorta, liver, kidney and lung by western blot. The levels of TGFb 1 ACT were unchanged in the plasma (Figure 4e ) and non-cardiac tissues (data not shown) in different groups of animals, confirming that TGFb 1 overexpression was limited to the heart. These data for the first time demonstrate that it is possible to increase TGFb 1 ACT selectively in the heart and that the transgene is expressed throughout the heart.
Effect of AAV/TGFb 1
ACT on basal cardiac function and infarct size following I-R. In our pilot experiments designed to examine cardiac function 6 weeks after TGFb 1 ACT delivery, we found that TGFb 1 ACT overexpression did not alter basal cardiac function (data not shown). There were no differences in the area at risk (AAR) in the two groups of rats. I-R in PBS-treated rats resulted in extensive infarct (42 ± 4% of AAR) as determined by triphenyl tetrazolium chloride staining. In contrast, AAV/TGFb 1 ACT -overexpressing rats had much smaller infarct (15±6% of AAR, Po0.01) (Figure 5b ).
Effect of AAV/TGFb 1 ACT on oxidative stress following I-R. Reactive oxygen species are released in the early stages of reperfusion, and NADPH oxidase activation is a major source of ROS. 10 Release of ROS causes peroxidation of lipids in the heart. Accordingly, we determined malondialdehyde (MDA) levels in the myocardial tissues. Control hearts showed minimal lipid peroxidation, whereas the PBS-treated hearts revealed a marked enhancement of lipid peroxidation following I-R. Overexpression of AAV/TGFb 1 ACT significantly reduced 
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A Dandapat et al I-R-induced lipid peroxidation (Po0.01 vs PBS-treated group) (Figure 5c ). We determined p67 phox NADPH oxidase expression in hearts of different groups of rats by immunohistochemistry and western blotting (Figures 5d and e) . NADPH oxidase p67 phox was only modestly expressed in the myocardium of sham control rat hearts; however, its expression was markedly increased following I-R. The upregulation of p67 phox NADPH oxidase was present throughout the left coronary artery (LCA)-supplied area with minimal increase in areas away from the core of the I-R zone. Hearts with AAV/TGFb 1 ACT overexpression exhibited a marked reduction in the expression of NADPH oxidase p67 phox despite the same degree of I-R (Po0.05 vs PBS-treated group).
The expression of Ik-Ba in the tissue homogenate was markedly decreased, whereas NF-kB (p65) was markedly increased in the nuclear extracts of the hearts treated with PBS and subjected to I-R (Po0.01 vs control group). On the other hand, hearts with AAV/TGFb 1 ACT overexpression showed much less NF-kB activation and preservation of Ik-Ba (both Po0.01 vs PBS group) (Figure 5f ).
Discussion
The present study makes several points: (1) TGFb 1 gene can be transferred into HL-1 mice cardiomyocytes very efficiently using AAV2; (2) TGFb 1 -overexpressing cardiomyocytes are protected from the adverse effects of H-R; and in this regard, TGFb 1 ACT is superior to TGFb 1 Latent ; (3) TGFb 1 ACT gene can be selectively upregulated in the rat hearts using AAV2 as vector with peak expression at about 6 weeks; and (4) TGFb 1 ACT -overexpressing hearts are protected from the deleterious effects of I-R.
Adeno-associated virus type 2 is clearly the best virus to use for long-term gene transduction and expression.
11
A recent study shows AAV2 transgene expression, determined by quantitative PCR, DNA fluorescence, in situ hybridization and immunohistochemistry, in dogs for over 4 years and in a patient for up to 3.7 years. 12 We therefore used AAV2 vector in the present study for overexpressing TGFb 1 ACT in the heart. A number of growth factors, including hepatocyte growth factor, basic fibroblast growth factor and TGFb 1, are protective to the tissues exposed to ischemia. 9, 13, 14 Human growth hormone has also been shown to improve cardiac function in patients with chronic heart failure. 15 We have been interested in TGFb 1 since this growth factor is abundant in platelets, which can limit ischemic injury to the heart. 9 In previous studies, TGFb 1 was shown to reduce apoptosis and necrosis in cultured rat cardiomyocytes. 3 Further, it is the conversion of TGFb 1 Latent to its active form TGFb 1 ACT that is deficient during ischemia. 9 In the present study, we demonstrate that TGFb 1 ACT is much more potent than TGFb 1 Latent in protecting cultured cardiac myocytes exposed to H-R. Cardiomyocyte injury was evaluated by quantitation of apoptosis (TUNEL staining, caspase-3 activity and relevant proteins expression), LDH release and cell viability (MTT assay). The mechanism of cell protection appears, in a large part, to be related to inhibition of NADPH oxidases, superoxide generation and redoxsensitive transcription factor NF-kB and its regulatory protein IkB-a.
Since the in vitro study suggested greater potency of TGFb 1 ACT (vs TGFb 1 Latent ), we chose TGFb 1 ACT as the transgene for in vivo overexpression. Rats were chosen 
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instead of mice because of their larger heart size for selective expression in the heart. We utilized a novel technique, that is selective injection of AAV/TGFb 1 ACT , to study its cardioprotective effect during I-R. The vector spread throughout the myocardium over the ensuing 6-week period as evident from diffused GFP expression. The selective upregulation of the transgene in the heart was demonstrated by enhanced mRNA and protein expression selectively in the cardiac tissues without a change in its levels in plasma and non-cardiac tissues. The 6-week time period during which the virus migrated throughout the heart is in support of previous studies in which AAV was shown to transfect entire muscle after injection at a few sites. 11, [16] [17] [18] The rat hearts with selective overexpression of the transgene were dramatically protected from the deleterious effect of I-R. Although we show the comparison with PBS as control for AAV/TGFb 1 ACT , the infarct size was similar to that in PBS-treated hearts in the few hearts injected with AAV/Neo indicating that the protective effect of AAV/TGFb 1 ACT was not as a result of AAV alone. The data in cultured cardiac myocytes showing lack of protective effects of AAV/Neo against H-R also support this contention. We measured cardiac injury as infarct size and myocardial MDA levels, which are standard methods for the quantitation of myocardial injury and lipid peroxidation. 19, 20 We also measured NADPH oxidase p67 phox and NF-kB p65 expression and their expression was reduced by transgene overexpression. The protective mechanism of TGFb 1 ACT against I-R injury in the rat hearts was similar to that seen in in vitro studies in mice cardiomyocytes.
The mechanism of the effects of TGFb 1 is diverse and has been reviewed in many recent publications, 6, [21] [22] [23] and involves activation of Smads, and other signals including p38 MAPK, Erk, JNK and TGF-activated kinase1. 21 TGFbs are among the most multifunctional cytokines known; they affect a variety of cell types and modulate multiple biological processes. Low concentrations of TGFb are growth promoting and high concentrations are growth inhibitory via modulation of PDGF-A and PDGF-B receptors. 23 Very small concentrations of TGFb 1 induce chemotaxis of neutrophils 24 and monocytes, 25 but large concentrations result in diminished leukocyte adhesion and migration. 26, 27 Whether any of these mechanisms are involved in tissue protection described in the present study is subject to conjecture. Certainly, we have shown that TGFb 1 ACT is 
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Study limitations
Although this study suggests that TGFb 1 overexpression in the ischemic heart has cardioprotective potential, the timing of the intervention is critical for the outcome. In this study, gene therapy was initiated 6 weeks before the ischemic event; this is clearly not possible in a clinical scenario. TGFb 1 is generally thought to be pro-fibrotic in the heart. Accordingly, further studies need to be performed, preferably with a gene switch to control TGb 1 ACT overexpression, such as vigilant vectors 28 to examine the effect of TGFb 1 overexpression on acute ischemic injury as well as long-term cardiac remodeling.
Materials and methods
Generation of recombinant AAV/TGFb 1 ACT , AAV/ TGFb 1 Latent and AAV/Neo
Rat TGFb 1 cDNA was generated as described previously. 29 To obtain TGFb 1
ACT
, site-directed mutagenesis of TGFb 1 cDNA was performed using the GeneEditor in vitro Site-Directed Mutagenesis System (Promega, San Luis, Obispo, CA, USA). The cysteines in positions 223 and 225 of TGFb 1 mRNA were substituted with serines. The mutation resulted in TGFb 1 protein in its biologically active form upon secretion. Latent TGFb 1 cDNA was acquired by amplification of high-fidelity PCR as described previously. 30 Rat TGFb 1 cDNA was used as template. The latent TGFb 1 cDNA is from nt 1247 to nt 1585. Finally, the mutant and latent TGFb 1 cDNA were verified by sequencing.
The latent or mutant rat TGFb 1 cDNA was inserted into AAV type 2 vector, dl6-95, in a manner described for other AAV vectors. 31 Hereafter, the recombinant AAV vector was referred to as AAV/TGFb 1 Latent or AAV/ TGFb 1 ACT , respectively. The AAV/Neo was generated as described earlier. 31 The virus stocks were generated and titered by dot blot hybridization as described previously. 31 The titers were calculated to be about 1 Â 10 11 encapsidated genomes per ml (10 10 infectious unit).
Cell culture and AAV vector infection
HL-1 adult murine cardiomyocytes were provided by Dr W C Claycomb (Louisiana State University, New Orleans, LA, USA) and cultured. 32 In brief, HL-1 cells were grown at 37 1C under 5% CO 2 in fibronectingelatin-coated flasks containing Claycomb medium supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin (Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine (Invitrogen) and 0.1 mM norepinephrine (Sigma, St Louis, MO, USA). To transfect the cultured cells, AAV vectors were added to cell culture dishes at an MOI of 10 4 and incubated with the cells for 72 h at 37 1C in 5% CO 2 /95% air. The infection efficiency was evaluated by AAV/GFP expression using fluorescent microscopy. AAV/GFP was obtained from the University of North Carolina, Gene Therapy Center, and the titer was 8 Â 10 12 virus particles per ml (3.1 Â 10 10 infectious units).
Exposure of cardiomyocytes to H-R
After 72 h of AAV vector (or only culture medium) transfection, myocytes were exposed to H-R and divided into the following groups: (1) control myocytes were continuously incubated in 95% air and 5% CO 2 ; (2) H-R plus saline myocytes were exposed to 24 h of hypoxia (95% N 2 and 5% CO 2 , PO 2 B30 mm Hg) followed by 3 h of reoxygenation (95% air and 5% CO 2 ); (3) H-R plus AAV/Neo myocytes were transfected with AAV/Neo and then exposed to H-R; (4) H-R plus AAV/TGFb 1 ACT myocytes were infected with AAV/TGFb 1 ACT and then exposed to H-R; (5) H-R plus AAV/TGFb 1 Latent myocytes transfected with AAV/TGFb 1 Latent were exposed to H-R. This degree of H-R has been shown to result in myocyte injury, including apoptosis and necrosis. 3, 33 At the end of H-R, culture medium was collected for the determination of LDH; myocytes were examined for measurement of cell viability, ROS release, apoptosis and expression of specific proteins.
Evaluation of cell viability and injury
Cell viability was assessed by MTT assay (Sigma). Results were normalized to the conversion of MTT in control cultures as 100%. Cell injury was quantitated by measuring LDH release, expressed as units per liter medium. 4 
Apoptosis analysis
In situ cell apoptosis was detected by using terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labeling (TUNEL) assay kit (Roche, Indianapolis, IN, USA). Ten randomly chosen fields (about 50 cells in each field) were observed per independent sample. The ratio of TUNEL-positive cells to the total number of nuclei stained with 4 0 ,6 0 -diamino-2-phenylindole was taken as index of apoptotic cells. Next, caspase-3-like protease activity in the lysate was measured using a colorimetric caspase-3 assay kit (Sigma). 34 The caspase-3 activity was expressed by value of OD 405 . The release of mitochondrial cytochrome c into the cytosol was assessed as an early indicator of apoptosis. 35 
Measurement of ROS in cardiomyocytes
Intracellular ROS generation was measured with the use of the fluorescent signal H 2 DCF-DA (10 mM; Cayman, Ann Arbor, MI, USA), a cell-permeable indicator for ROS. H 2 DCF-DA is nonfluorescent until the acetate groups are removed by intracellular ROS. The ROSmediated fluorescence was observed under a fluorescent microscope (Nikon, Eclipse E600) with excitation set at 502 nm and emission set at 523 nm.
AAV vector inoculation in vivo
Male SD rats weighing 120-150 g (Charles River, Wilmington, MA, USA) were anesthetized with pentobarbital sodium (60 mg kg À1 , i.p.), intubated and ventilated (Model 681, Harvard Apparatus). A thoracotomy incision was made in the fourth intercostal space, and the heart exposed. Viral vector in 100 ml of PBS or PBS alone was injected directly into the cardiac tissues at four different sites around the expected ischemic region in the LCA territory. After injections, air was sucked out of the thoracic cavity to restore negative pressure before closing the incision. After 2 or 6 weeks of intramyocardial TGFb 1 and apoptosis and ischemia-reperfusion injury A Dandapat et al injections, the hearts were harvested to examine for GFP expression in situ using fluorescent microscopy and expression of TGFb 1 ACT (mRNA and protein).
5,29
Myocardial ischemia-reperfusion protocol After 6 weeks of intramyocardial injections of viral vectors or PBS, rats were anesthetized, intubated and mechanically ventilated. A left thoracotomy was performed to expose the heart. The LCA was ligated 2-3 mm proximal to the origin of first diagonal branch with a 5-0 silk suture. Successful cessation of blood flow was indicated by elevation of ST segment on electrocardiogram and cyanosis of anterior LV wall. All animals were subjected to 60 min of LCA occlusion followed by 60 min of reperfusion, except the sham control group. All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Usage Committee of University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Determination of infarct size
At the end of reperfusion, LCA was re-occluded in the same location as before, and 1 ml 1% Evans blue (Sigma) was injected into the LV cavity and was allowed to perfuse the non-ischemic portions of the heart. The LV was sliced into 1-mm-thick sections from the apex to base. The slices were incubated in 1 % triphenyl tetrazolium chloride (Sigma) at 37 1C for 15 min to stain the viable myocardium brick red and then fixed in a 10% formalin solution for 24 h. Each slice was imaged with computer-assisted planimetry (NIH Image J 1.34 s) by an observer blinded to sample identity and following parameters was analyzed: (1) AAR as a percent of LV (AAR/LV), (2) the infarct area (IA) as a percent of AAR (IA/AAR).
Immunofluorescence TGFb 1 staining in myocardial tissues
At the end of I-R, entire LV was harvested for immunofluorescent TGFb 1 staining. 36 
Determination of MDA levels in myocardium
At the end of reperfusion, entire LV was homogenized in ice-cold 20 mM phosphate buffer. MDA was measured in the LV homogenate and expressed as mmol MDA per g protein. 20 Immunohistochemical localization of NADPH oxidase
Immunohistochemical characterization was made in formalin-fixed samples from at least four rat hearts in each group (7-10 discontinuous slides were used in every heart) using a biotin-streptavidin detection system with diaminobenzidine as the chromogen (Santa Cruz, Santa Cruz, CA, USA). 37 The primary polyclonal goat antibody to p67phox was diluted at 1:50. Goat serum applied instead of primary antibody was used as a negative control.
Expression analysis
Protein was extracted from entire LV or HL-1 cells. Western blotting was performed as described above for cytochrome c using primary antibodies against Bax, Bcl-2, NADPH oxidase subunits (p22 phox 
Statistical analysis
Data are expressed as means ± s.e.m. The between-group difference in the infarct size was evaluated by unpaired t-test. All other data values were analyzed by using ANOVA and the Newman-Keuls-Student t-test. The significance level was chosen as Po0.05.
